A Multi-center, Cluster-randomized, Prospective, Observational Study

Boryung Pharmaceutical Co., Ltd1 site in 1 country3,554 target enrollmentAugust 9, 2017

ConditionsHypertension

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Hypertension
Sponsor: Boryung Pharmaceutical Co., Ltd
Enrollment: 3554
Locations: 1
Primary Endpoint: Rate of reaching target blood pressure
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the effect of home blood pressure monitoring on controlling blood pressure and correlation between home blood pressure and clinic blood pressure in hypertensive patients receiving two or more concomitant antihypertensive agents including fimasartan

Detailed Description

A multi-center, cluster-randomized, prospective, observational study

Registry

clinicaltrials.gov

Start Date

August 9, 2017

End Date

February 28, 2019

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

Boryung Pharmaceutical Co., Ltd

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects who voluntarily signed informed consent for participating in this clinical study
•Male and female over the age of 19
•Hypertensive patients receiving two or more concomitant anti-hypertensive agents including fimasartan

Exclusion Criteria

•Renal dialysis patients.
•Diabetic nephropathy patients taking angiotensin-converting enzyme inhibitor.
•Severe renal disorder
•Subjects with hereditary disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
•Medical history with hypersensitivity to Fimasartan
•Pregnant women or lactating female.
•Participate in another clinical trial.